| Patient | Sun Yat-sen |
|---|---|
| Date of birth | 1968-11-12 |
| Identifiers | MRN HR-ET016-SYN; SSN (made up) 000-16-4183 |
| Document date | 2026-06-01 |
| Author | Wen-Li Huang, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Staging laparoscopy result, tumor board recommendation, and first cycle of treatment. [S]
Mr. Sun returns two weeks after the consultation and five days after the staging laparoscopy. At laparoscopy the surgeon found several small nodules on the lining of the abdomen and the omentum, and their biopsy shows adenocarcinoma of the same type. The tumor board met two days later and advised against an operation and for chemoimmunotherapy. He has recovered from the laparoscopy; the port and the small wounds are healing. The ache under his ribs is unchanged at 2 of 10. He said he had expected this, as a physician, but found it hard to hear. He has slept poorly for several nights. He wants to start treatment today if he is fit for it and asked how long treatment might keep him working. [S]
| Element | Detail |
|---|---|
| Staging laparoscopy | Peritoneal and omental nodules; biopsy adenocarcinoma |
| Tumor board | Not resectable; first-line chemoimmunotherapy advised |
| Recovery | Wounds and port healing |
| Mood and sleep | Finds the news hard; sleeping poorly |
| His question | How long treatment may keep him working |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; weight 60.0 kg; no fever |
| Gastrointestinal | Positive | Ache under the right ribs 2 of 10; no jaundice or vomiting |
| Psychiatric | Positive | Low at times and sleeping poorly since the result; no thoughts of self-harm |
| Integumentary | Negative | Port and laparoscopy wounds healing without redness |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day | Two tablets by mouth every 8 hours as needed, no more than 3,000 mg a day | Oral route | 2026-05-04 | active | S |
| Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles | Intravenous route | 2026-06-01 | active | S |
| Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycle | Days 1 and 8 of each 21-day cycle, up to 8 cycles, with hydration | Intravenous route | 2026-06-01 | active | S |
| Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycle | Day 1 of each 21-day cycle with chemotherapy, then every 4 weeks alone | Intravenous route | 2026-06-01 | active | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet by mouth every 8 hours as needed for nausea | Oral route | 2026-06-01 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-01 | Body height | 165 | cm | S |
| 2026-06-01 | Body weight | 60 | kg | S |
| 2026-06-01 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-06-01 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-06-01 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-06-01 | Heart rate | 84 | /min | S |
| 2026-06-01 | Respiratory rate | 16 | /min | S |
| 2026-06-01 | Body temperature | 36.7 | Cel | S |
| 2026-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-01 | Leukocytes [#/volume] in Blood by Automated count | 7.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-01 | Neutrophils [#/volume] in Blood by Automated count | 4.9 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-06-01 | Hemoglobin [Mass/volume] in Blood | 12.2 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-06-01 | Platelets [#/volume] in Blood by Automated count | 318 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-01 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-01 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-06-01 | Albumin [Mass/volume] in Serum or Plasma | 3.4 | g/dL | 3.5-5 g/dL | Low | S |
| 2026-06-01 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.2-1.2 mg/dL | Normal | S |
| 2026-06-01 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 236 | U/L | 40-129 U/L | High | S |
| 2026-06-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 10-40 U/L | High | S |
| 2026-06-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 | U/L | 7-55 U/L | Normal | S |
| 2026-06-01 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-06-01 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 498 | U/mL | <=35 U/mL | High | S |
| 2026-06-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-06-01 | ECOG Performance Status score | 1 | {score} | S |
Vital signs recorded on 2026-06-01; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, composed; blood pressure 126/80, pulse 84; weight 60.0 kg; no jaundice |
| Abdomen | Healing laparoscopy wounds; mass 4 cm below the right costal margin, unchanged; no ascites |
| Chest wall | Port site clean and dry |
| Ears, nose, mouth, and throat | Hears a whispered voice in both ears |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arranged | resolved | confirmed | R19.01 | S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis. |
| Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinoma | active | confirmed | C23 | S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy. |
| Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitored | active | confirmed | Z86.19 | S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis. |
| Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectable | active | confirmed | C78.6 | S — Synthetic finding anchored to the peritoneal metastases reported at autopsy. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Staging laparoscopy | Before resection of gallbladder cancer | Completed today | Peritoneal and omental nodules; biopsy adenocarcinoma: M1 |
| Referral | Multidisciplinary tumor board | Before treatment, and when the stage changes | Completed today | Not resectable; gemcitabine, cisplatin and durvalumab advised |
| Imaging | CT of the chest, abdomen and pelvis | At staging, then every 2 to 3 months on treatment | Due | Baseline from staging; restaging after three cycles |
| Laboratory | CA 19-9 (and CEA when raised) | At diagnosis, then with each cycle or restaging | Completed today | CA 19-9 498 U/mL at baseline |
| Laboratory | Blood count with neutrophils | Before every dose (days 1 and 8) | Completed today | White cells 7.4, neutrophils 4.9, hemoglobin 12.2 g/dL, platelets 318 |
| Laboratory | Creatinine and eGFR | Before every dose (days 1 and 8) | Completed today | Creatinine 0.84 mg/dL, eGFR 102; adequate for cisplatin |
| Laboratory | Magnesium and potassium | Before every dose (days 1 and 8) | Completed today | Magnesium 2.0 mg/dL, potassium 4.3 mmol/L, sodium 137 mmol/L |
| Laboratory | Liver tests (bilirubin, alkaline phosphatase, AST, ALT, albumin) | Before every dose (days 1 and 8) | Completed today | Bilirubin 0.8 mg/dL, alkaline phosphatase 236, AST 52, ALT 44 U/L, albumin 3.4 g/dL |
| Laboratory | TSH | Baseline, then every 4 to 6 weeks on durvalumab | Completed today | 1.9 mIU/L at baseline |
| Laboratory | Glucose | Baseline, then with each pre-dose chemistry panel on durvalumab | Deferred | Missed: today's pre-treatment panel was ordered as a renal panel with magnesium and did not include glucose. Glucose was 98 mg/dL at intake and he has no thirst or excess urination, so no harm is apparent. Corrective action: glucose added to the standing pre-dose order from the next draw |
| Laboratory | HBV DNA and ALT (resolved hepatitis B) | Every 3 months during treatment and for 6 to 12 months after | Up to date | HBV DNA undetectable before treatment; ALT 44 U/L today (liver tests above); next in 2 to 3 months |
| Examination | Hearing (cisplatin) | Baseline before cisplatin, then by symptoms each cycle | Deferred | Missed: no baseline audiogram before the first cisplatin dose; whispered-voice test normal today and no hearing symptoms. The lower 25 mg/m2 dose carries less risk; corrective action is to ask about hearing at each cycle and obtain an audiogram for any change |
| Survey | ECOG performance status | Every visit | Completed today | ECOG 1 |
| Examination | Weight and nutrition | Every visit | Completed today | 60.0 kg; dietitian advice followed |
| Survey | Pain | Every visit | Completed today | 2 of 10 on acetaminophen |
| Survey | Distress and depression (PHQ-9) | At diagnosis and at each change in treatment | Completed today | PHQ-9 6, mild; no thoughts of self-harm |
| Laboratory | Comprehensive genomic profiling of tumor tissue | At diagnosis of advanced disease | Ordered | Pending |
| Referral | Specialist palliative care | From the diagnosis of advanced cancer | Referred | First visit next week |
| Medication safety | Immune-related side effects (diarrhea, rash, cough or breathlessness, fatigue, endocrine symptoms) | Teaching before the first dose, then every visit | Completed today | Taught today with written information |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022); Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021)
Follow-up: Cycle 1 day 8 next week; palliative care next week. Visit before cycle 4 with a restaging CT. Next scheduled visit 2026-08-03: before cycle 4: restaging CT, tumor marker, toxicity review, hepatitis B monitoring, and genomic profiling result. [S]